🇺🇸 SER-109 in United States
2 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 2
Most-reported reactions
- Abdominal Pain — 1 report (50%)
- Diarrhoea — 1 report (50%)
Other Infectious Disease / Gastroenterology approved in United States
Frequently asked questions
Is SER-109 approved in United States?
SER-109 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for SER-109 in United States?
Seres Therapeutics, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.